Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets?

Frontiers in Physiology

Volumn 3 NOV, Issue , 2012, Pages

  Zhang, Zhuo ^a   Yang, Yan ^b   Hill, Michael A ^b,c   Wu, Jianbo ^a,b  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

Author keywords

Atherothrombosis; C reactive protein; Platelet; Reactive oxygen species; Vascular cells

Indexed keywords

EID: 84870942832     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00433     Document Type: Article

References (78)

1. Basta, G., Lazzerini, G., Del Turco, S., Ratto, G. M., Schmidt, A. M., and De Caterina, R. (2005). At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler. Thromb. Vasc. Biol. 25, 1401-1407.
2. Bharadwaj, D., Stein, M. P., Volzer, M., Mold, C., and Du Clos, T. W. (1999). The major receptor for Creactive protein on leukocytes is fcgamma receptor II. J. Exp. Med. 190, 585-590.
3. Bisoendial, R. J., Kastelein, J. J., Peters, S. L., Levels, J. H., Birjmohun, R., Rotmans, J. I., et al. (2007). Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48, 952-960.
4. Bisoendial, R. J., Kastelein, J. J. P., Levels, J. H. M., Zwaginga, J. J., van den Bogaard, B., Reitsma, P. H., et al. (2005). Activation of inflammation and coagulation after infusion of Crective protein in humans. Circ. Res. 96, 714-716.
5. Blackburn, R., Giral, P., Bruckert, E., André, J. M., Gonbert, S., Bernard, M., et al. (2001). Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 21, 1962-1968.
6. Bonomini, F., Tengattini, S., Fabiano, A., Bianchi, R., and Rezzani, R. (2008). Atherosclerosis and oxidative stress. Histol. Histopathol. 23, 381-390. [Review].
7. Bouloumie, A., Marumo, T., Lafontan, M., and Busse, R. (1999). Leptin induces oxidative stress in human endothelial cells. FASEB J. 13, 1231-1238.
8. Cheryk, L. A., Hayes, M. A., and Gentry, P. A. (1996). Modulation of bovine platelet function by C-reactive protein. Vet. Immunol. Immunopathol. 52, 27-36.
9. Danenberg, H. D., Kantak, N., Grad, E., Swaminathan, R. V., Lotan, C., and Edelman, E. R. (2007). C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur. J. Haematol. 78, 246-252.
10. Danenberg, H. D., Szalai, A. J., Swaminathan, R. V., Peng, L., Chen, Z., Seifert, P., et al. (2003). Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice. Circulation 108, 512-515.
11. Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., et al. (2004). C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397.
12. Davì, G.,and Patrono,C. (2007).Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494.
13. Devaraj, S., Dasu, M. R., Singh, U., Rao, L. V., and Jialal, I. (2009). Creactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 203, 67-74.
14. Devaraj, S., and Jialal, I. (2011). Creactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler. Thromb. Vasc. Biol. 31, 1397-1402.
15. Devaraj, S., Xu, D. Y., and Jialal, I. (2003). C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404.
16. Dong, Q., and Wright, J. R. (1996). Expression of C-reactive protein by alveolar macrophages. J. Immunol. 156, 4815-4820.
17. Eisenhardt, S. U., Habersberger, J., Murphy, A., Chen, Y. C., Woollard, K. J., Bassler, N., et al. (2009). Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res. 105, 128-137.
18. Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M. B., Thompson, S. G., Collins, R., et al. (2010). Creactive protein concentration and risk of coronary heart disease,stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140.
19. Fiedel, B. A., and Gewurz, H. (1976). Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J. Immunol. 116, 1289-1294.
20. Filep, J. G. (2009). Platelets affect the structure and function of C-reactive protein. Circ. Res. 105, 109-111.
21. Filep, J. G., Hermán, F., Kelemen, E., and Földes-Filep, E. (1991). C-reactive protein inhibits binding of plateletactivating factor to human platelets. Thromb. Res. 61, 411-421.
22. Freedman, J. E., Farhat, J. H., Loscalzo, J., and Keaney, J. F. (1996). Alphatocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 10, 2434-2440.
23. Gabay, C., and Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448-454.
24. Giacco, F., and Brownlee, M. (2010). Oxidative stress and diabetic complications. Circ. Res. 107,1058-1070. [Review].
25. Guzik, T. J., Sadowski, J., Guzik, B., Jopek, A., Kapelak, B., Przybylowski, P., et al. (2006). Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 26, 333-339.
26. Hak,A. E., Stehouwer, C. D., Bots, M. L., Polderman, K. H., Schalkwijk, C. G., Westendorp,I. C.,et al. (1999).Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19, 1986-1991.
27. Heinrich, J., Schulte, H., Schonfeld, R., Kohler, E., and Assmann, G. (1995). Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb. Haemost. 73, 374-379.
28. Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., and Talmud, P. J. (2009). C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin. Chem. 55, 239-255.
29. Hirschfield, G. M., Gallimore, J. R., Kahan, M. C., Hutchinson, W. L., Sabin, C. A., Benson, G. M., et al. (2005). Transgenic human Creactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 102, 8309-8314.
30. Huang, Y., Mironova, M., and Lopes-Virella, M. F. (1999). Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19, 2640-2467.
31. Hulsmans, M., and Holvoet, P. (2010). The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell. Mol. Med. 14,70-78. [Review].
32. Ikeda, H., Koga, Y., Oda, T., Kuwano, K., Nakayama, H., Ueno, T., et al. (1994). Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J. Am. Coll. Cardiol. 24, 1749-1756.
33. Irani, K. (2000). Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 87, 179-183.
34. Jabs, W. J., Theissing, E., Nitschke, M., Bechtel, J. F., Duchrow, M., Mohamed, S., et al. (2003). Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 108, 1428-1431.
35. Järvisalo, M. J., Harmoinen, A., Hakanen, M., Paakkunainen, U., Viikari, J., Hartiala, J., et al. (2002). Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler. Thromb.Vasc. Biol. 22, 1323-1328.
36. Kataoka, H., Kume, N., Miyamoto, S., Minami, M., Morimoto, M., Hayashida,K.,et al. (2001). Oxidized LDL modulates Bax/Bcl-2 through the lectinlike ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21, 955-960.
37. Keaney, J. F. Jr., Guo, Y., Cunningham, D., Shwaery, G. T., Xu, A., and Vita, J. A. (1996). Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J. Clin. Invest. 98, 386-394.
38. Khera, A., de Lemos, J. A., Peshock, R. M., Lo, H. S., Stanek, H. G., Murphy, S. A., et al. (2006). Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas heart study. Circulation 113, 38-43.
39. Khreiss, T., József, L., Potempa, L. A., and Filep, J. G. (2004). Opposing effects of C-reactive protein isoforms on shear-induced neutrophilplatelet adhesion and neutrophil aggregation in whole blood. Circulation 110, 2713-2720.
40. Khreiss, T., József, L., Potempa, L. A., and Filep, J. G. (2005). Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ. Res. 97, 690-697.
41. Kobayashi, S., Inoue, N., Ohashi, Y., Terashima, M., Matsui, K., Mori, T., et al. (2003). Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler. Thromb. Vasc. Biol. 23, 1398-1404.
42. Lee,Y. W., and Hirani,A. A. (2006). Role of interleukin-4 in atherosclerosis. Arch. Pharm. Res. 29,1-15. [Review].
43. Lin, R., Liu, J., Gan, W., and Yang, G. (2004). C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol. Pharm. Bull. 27, 1537-1543.
44. Molins, B., Peña, E., Vilahur, G., Mendieta, C., Slevin, M., and Badimon, L. (2008). C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler. Thromb. Vasc. Biol. 28, 2239-2246.
45. Nordestgaard, B. G., and Zacho, J. (2009). Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr. Metab. Cardiovasc. Dis. 19, 521-524.
46. Palinski, W., Rosenfeld, M. E., YläHerttuala, S., Gurtner, G. C., Socher, S. S., Butler, S. W., et al. (1989). Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. U.S.A. 86, 1372-1376.
47. Pasceri, V., Cheng, J. S., Willerson, J. T., Yeh, E. T., and Chang, J. (2001). Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531-2534.
48. Pasceri, V., Willerson, J. T., and Yeh, E. T. (2000). Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165-2168.
49. Paul, A., Ko, K. W. S., Li, L., Yechoor, V., McCrory, M. A., Szalai, A. J., et al. (2004). C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109, 647-655.
50. Pepys, M. B. (2008). C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat. Clin. Pract. Nephrol. 4, 234-235.
51. Potempa, L. A., Zeller, J. M., Fiedel, B. A., Kinoshita, C. M., and Gewurz, H. (1988). Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 12, 391-405.
52. Przyklenk, K., and Kloner, R. A. (1993). Oxygen radical scavenging agents as adjunct therapy with tissue plasminogen activator in a canine model of coronary thrombolysis. Cardiovasc. Res. 27, 925-934.
53. Qamirani, E., Ren, Y., Kuo, L., and Hein, T. W. (2005). CRP inhibits endothelium-dependent NOmediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler. Thromb. Vasc. Biol. 25, 995-1001.
54. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M. Jr., Kastelein, J. J., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N. Engl. J. Med. 359, 2195-2207.
55. Ridker, P. M., MacFadyen, J., Libby, P., and Glynn, R. J. (2010). Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Am. J. Cardiol. 106, 204-209.
56. Ryu, J., Lee, C. W., Shin, J. A., Park, C. S., Kim, J. J., Park, S. J., et al. (2007). FcgammaRIIa mediates Creactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc. Res. 75, 555-565.
57. Schönbeck,U.,and Libby,P. (2001). The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58, 4-43.
58. Schwedler, S. B., Hansen-Hagge, T., Reichert, M., Schmiedeke, D., Schneider, R., Galle, J., et al. (2009). Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin. Chem. 55, 1728-1731.
59. Singh, U., Dasu, M. R., Yancey, P. G., Afify, A., Devaraj, S., and Jialal, I. (2008). Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J. Lipid Res. 49, 1015-1023.
60. Singh, U., Devaraj, S., Dasu, M. R., Ciobanu, D., Reusch, J., and Jialal, I. (2006). C-reactive protein decreases interleukin-10 secretion in activated human monocytederived macrophages via inhibition of cyclic AMP production. Arterioscler. Thromb. Vasc. Biol. 26, 2469-2475.
61. Singh, U., Devaraj, S., and Jialal, I. (2005). C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant.Arterioscler.Thromb. Vasc. Biol. 25, 2216-2221.
62. Singh, U., Devaraj, S., Vasquez-Vivar, J., and Jialal, I. (2007). C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J. Mol. Cell. Cardiol. 43, 780-791.
63. Sorescu, D., Weiss, D., Lassègue, B., Clempus,R. E.,Szöcs,K.,Sorescu,G. P., et al. (2002). Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105, 1429-1435.
64. Sun, H., Koike, T., Ichikawa, T., Hatakeyama, K., Shiomi, M., Zhang, B., et al. (2005). C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am. J. Pathol. 167, 1139-1148.
65. Tanigaki, K., Mineo, C., Yuhanna, I. S., Chambliss, K. L., Quon, M. J., Bonvini, E., et al. (2009). C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosinebased inhibition motif of FcgammaRIIB and SHIP-1. Circ. Res. 104, 1275-1282.
66. Thomas, S. R., Witting, P. K., and Drummond, G. R. (2008). Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10, 1713-1765. [Review].
67. Trion, A., de Maat, M. P. M., Jukema, J. W., van der Laarse, A., Maas, M. C., Offerman, E. H., et al. (2005). No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-Leiden/human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol. 25, 1635-1640.
68. Venugopal,S. K.,Devaraj,S.,andJialal,I. (2003). C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108, 1676-1678.
69. Wang, D., Oparil, S., Chen, Y., McCrory, M., Skibinski, G., Feng, W., et al. (2005). Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol. 25, 2094-2099.
70. Willeit, J., Kiechl, S., Oberhollenzer, F., Rungger, G., Egger, G., Bonora, E., et al. (2000). Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 20, 529-537.
71. Wu, J., Stevenson, M. J., Brown, J. M., Grunz, E. A., Strawn, T. L., and Fay, W. P. (2008). C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler. Thromb. Vasc. Biol. 28, 698-704.
72. Xu, X. P., Meisel, S. R., Ong, J. M., Kaul, S., Cerceck, B., and Shah, P. K. (1999). Oxidized lowdensity lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocytederived macrophages. Circulation 99, 993-998.
73. Yaron, G., Brill, A., Dashevsky, O.,Yosef-Levi, I. M., Grad, E., Danenberg, H. D., et al. (2006). C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br. J. Haematol. 134, 426-431.
74. Ylä-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., et al. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84, 1086-1095.
75. Zacho, J., Tybjaerg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., and Nordestgaard, B. G. (2008). Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908.
76. Zebrack, J. S., Muhlestein, J. B., Horne, B. D., and Anderson, J. L. (2002). C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J. Am. Coll. Cardiol. 39, 632-637.
77. Zeller, J. M., and Sullivan, B. L. (1992). C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J. Leukoc. Biol. 52, 449-455.
78. Zhao, X. Q., Zhang, M. W., Wang, F., Zhao, Y. X., Li, J. J., Wang, X. P., et al. (2011). CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J. Lipid Res. 52, 923-933.